Skip to main content
Edwards Lifesciences10-Q: Product launch

FDA approved SAPIEN 3 transcatheter pulmonic valve delivery system in January 2026

Source: Autobound Signal API · 68 signals tracked for Edwards Lifesciences · updated

Get Edwards Lifesciences' live signals in Claude or ChatGPT, or by API

AskWhat changed at Edwards Lifesciences this week? Use Autobound signals for edwards.com.

What happened

Edwards received FDA approval in January 2026 for the SAPIEN 3 transcatheter pulmonic valve delivery system for pediatric and adult congenital heart disease patients. Commercial expansion for this newly approved delivery system may require specialized marketing, clinical training, and distribution support.

Source

SEC EDGARMay 6, 2026

Quarterly report (Form 10-Q)

Edwards Lifesciences 10-Q for Quarter ended Mar 31, 2026

Filing excerpt

In January 2026, we received United States Food and Drug Administration approval for the SAPIEN 3 transcatheter pulmonic valve delivery system, an advancement designed specifically to support pediatric and adult patients living with congenital heart disease.

sec.gov/Archives/edgar/data/1099800/000109980026000026/ew-20260331.htmRead the full source

Other signals in this filing (3)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Product launch

What this signalsFilings often name leadership changes, deals and spending plans.

Period
Quarter ended Mar 31, 2026
Fiscal year end
03/31
Filed
May 6, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Details

CIK
1099800
Accession number
0001099800-26-000026
Timeframe
Current quarter
Quarter
Q1
Filing year
2026
Period end date
Mar 31, 2026
Why it matters
Go-to-market support
Signal category
Strategic

Topics and mentions

Regions named

  • United States

Extraction

Confidence
High
Relevance
80%
Sentiment
Positive
Detected
Nov 9, 2026
signal_type
sec-10q
signal_subtype
productLaunch

Use this data

Get every 10-Q signal for Edwards Lifesciences and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Edwards Lifesciences this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/0a530226-529c-4011-952e-40db6569eaac returns this record as JSON. POST /v1/companies/enrich returns every signal for edwards.com.

{
  "signal_id": "0a530226-529c-4011-952e-40db6569eaac",
  "signal_type": "sec-10q",
  "signal_subtype": "productLaunch",
  "detected_at": "2026-11-09T06:27:08.053+00:00",
  "company": {
    "name": "Edwards Lifesciences",
    "domain": "edwards.com"
  },
  "data": {
    "detail": "Edwards received FDA approval in January 2026 for the SAPIEN 3 transcatheter pulmonic valve delivery system for pediatric and adult congenital heart disease patients. Commercial expansion for this newly approved delivery system may require specialized marketing, clinical training, and distribution support.",
    "metrics": {
      "timeframe": "current_quarter"
    },
    "quarter": "Q1",
    "summary": "FDA approved SAPIEN 3 transcatheter pulmonic valve delivery system in January 2026",
    "excerpts": "In January 2026, we received United States Food and Drug Administration approval for the SAPIEN 3 transcatheter pulmonic valve delivery system, an advancement designed specifically to support pediatric and adult patients living with congenital heart disease.",
    "relevance": 0.8,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/1099800/000109980026000026/ew-20260331.htm",
    "filing_date": "2026-05-06",
    "filing_year": 2026,
    "fiscal_year": 2026,
    "fiscal_year_end": "03/31",
    "period_end_date": "2026-03-31",
    "sales_relevance": "Go-to-market support",
    "signal_category": "strategic",
    "regions_mentioned": [
      "United States"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.